Vericel/VCEL

$47.99

2.67%
-
1D1W1MYTD1YMAX

About Vericel

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

Ticker

VCEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Dominick Colangelo

Employees

314

Headquarters

Cambridge, United States
Website
vcel.com

Vericel Metrics

BasicAdvanced
$2.3B
Market cap
5017.78
P/E ratio
$0.01
EPS
1.74
Beta
-
Dividend rate
$2.3B
1.74447
$53.05
$30.18
416K
5.202
4.83
0.066
0.066
0.15%
0.21%
0.16%
5,017.782
11.221
9.945
10.263
1,145.101
22.72%
102.64%
16.73%

What the Analysts think about Vericel

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
15.65% upside
High $57.00
Low $53.00
$47.99
Current price
$55.50
Average price target

Vericel Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-7.42% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$51M
-21.11%
Net income
-$3.8M
-129.46%
Profit margin
-7.42%
-137.34%

Vericel Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.11
-$0.08
$0.26
-$0.08
-
Expected
-$0.15
-$0.12
$0.17
-$0.11
-$0.09
Surprise
-27.54%
-34.52%
52.64%
-27.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vericel stock?

Vericel (VCEL) has a market cap of $2.3B as of May 30, 2024.

What is the P/E ratio for Vericel stock?

The price to earnings (P/E) ratio for Vericel (VCEL) stock is 5017.78 as of May 30, 2024.

Does Vericel stock pay dividends?

No, Vericel (VCEL) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Vericel dividend payment date?

Vericel (VCEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Vericel?

Vericel (VCEL) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Vericel stock price target?

The target price for Vericel (VCEL) stock is $55.5, which is 15.65% above the current price of $47.99. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vericel stock

Buy or sell Vericel stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing